Pharmaceutical Industry Terrified Weed Legalization Will Put Them Out of Business
The opioid epidemic is a real issue in America. So much so that the U.S. Attorney General Loretta Lynch started telling young folks that marijuana isn’t really the problem. Instead, Lynch explained, legally prescribed medications are to blame for the increase in opioid abuse.
But while learning that the head of the United States Department of Justice has just argued that weed does not represent a real threat may sound promising, it’s important to remember that marijuana is still a Schedule I drug. Meaning that the federal government still sees marijuana as a substance “with no currently accepted medical use and a high potential for abuse.”
Recently, a group of marijuana legalization activists got an initiative known as Proposition 205 in the ballot in Arizona.
The initiative would allow Arizona residents who are older than 21 to possess up to an ounce of marijuana in public. Prop 205 would also allow consumers to grow up to six plants at home, giving them the option to give other adults up to an ounce at a time of its produce “without remuneration.”
But with the good news came another discovery.
The group that, alone, donated $500,000 to the effort to oppose the Arizona marijuana legalization campaign, is a local pharmaceutical company known as Insys, and it produces oral sprays used in the delivery of an opioid painkiller known as fentanyl.
According to Reason, the same company is planning on marketing yet another device that would deliver dronabinol, a synthetic version of tetrahydrocannabinol, or THC: The main mind-altering ingredient in cannabis.
When donating to kill the initiative, the company contended that its opposition to marijuana legalization is due to Prop 205’s “[failure] to to protect the safety of Arizona’s citizens, and particularly its children.” According to Reason’s Jacob Sullum, what Insys is truly worried about is “the impact that legalization might have on its bottom line, since marijuana could compete with its products.”
And why is Insys so concerned? Perhaps because a recent study published in the American Journal of Public Health contends that, in states where marijuana use is legal to a certain extent, fatally injured drivers are “less likely to test positive for opioids.” Sullum adds that this finding, along with the results of other studies show that “making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.”
The data analyzed by researchers comes from the Fatality Analysis Reporting System (FARS). By looking at the data gathered from 18 states where 80 percent of drivers who died in auto crashes were drug-tested, researchers found that, between 1999 and 2013, drivers between the ages of 21 and 40 were half as likely to test positive for opioids where medical marijuana laws had been implemented.
In these same states, researchers found that painkiller prescriptions fell by 3,645 daily doses per physician. Researchers concluded that “the passage of the medical marijuana laws” are directly associated with “the observed shifts in prescribing patterns.”
As the industry begins to fear the consequences of ending the drug war, we begin to understand that their dominance over the market is mainly due to their rent-seeking practices, which keep their leaders close to lawmakers, helping the industry to exert enough influence to sway public policy in a way that benefits them.
Without the presence of a government body giving companies special protections while outlawing particular drug transactions, drug providers are able to compete freely and in the open, giving consumers better and safer options.
It’s time to finally put an end to the drug war and admit that, rent-seeking will never help the nation heal from all of the negative consequences of our country’s ongoing romance with crony capitalism.